Polymyxin B 10,000units/ml / Trimethoprim 1mg/ml eye drops
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · Randomised trials: 6 · 1981–2026
Showing the 50 most relevant studies, sorted by most relevant.
Xavier Anglaret, Geneviève Chêne, Alain Attia, et al.
The Lancet, 1999
Stefan Z Wiktor, Madeleine Sassan-Morokro, Alison D Grant, et al.
The Lancet, 1999
James M McCarty, George Richard, Werner Huck, et al.
The American Journal of Medicine, 1999
M. Vaara, T. Vaara, M. Jensen, et al.
FEBS Letters, 1981
L. Williams, Y. Malhotra, Barbra L. Murante, et al.
The Journal of pediatrics, 2013
- Conjunctiva
- Haemophilus influenzae
- Streptococcus pneumoniae
Haim Tsubery, Itzhak Ofek, Sofia Cohen, et al.
Journal of Medicinal Chemistry, 2000
Zhang C, Zhu J, Luo J, et al.
2026
Nocardia farcinica is a highly virulent opportunistic pathogen with a marked propensity to cause disseminated infection in immunocompromised hosts. Its clinical manifestations are often nonspecific, conventional empirical anti-infective therapy may be ineffective, and both misdiagnosis and mortality rates remain high. We report the case of a 20-year-old man with membranous nephropathy who developed multiple cutaneous and deep soft-tissue abscesses, fever, and pulmonary infiltrates after 7 months of dual immunosuppressive therapy with methylprednisolone and tacrolimus. Initial empirical treatment with oxacillin plus moxifloxacin failed to control the infection, and the patient continued to experience high fever with persistently elevated inflammatory markers. Direct smear examination of pus specimens showed weakly acid-fast, branching filamentous organisms, and culture followed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) identified the pathogen as Nocardia farcinica. According to antimicrobial susceptibility testing, therapy was adjusted to trimethoprim-sulfamethoxazole (SMZ-TMP) combined with amoxicillin/clavulanate potassium. The patient subsequently became afebrile, the abscesses gradually decreased in size, and inflammatory markers improved substantially. After clinical stabilization, he was discharged on continued oral anti-infective therapy and showed no evidence of recurrence during 12 months of outpatient follow-up. Together with a review of the literature, this report discusses the clinical features, etiological diagnostic strategies, and susceptibility-guided anti-infective regimens for disseminated Nocardia farcinica infection in immunosuppressed patients, with the aim of providing a practical reference for clinical diagnosis and treatment.
Abstract licence: CC BY-NC
Akira Nagatomo, Koshiro Watanabe, Hiroshi Kunikane, et al.
Lung Cancer, 1998
S. Mian, C. Hood
2012
A. Wiese, M. Münstermann, T. Gutsmann, et al.
Journal of Membrane Biology, 1998
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.